NRAS G13 in MDS-LR — progression-risk marker. No targeted therapy; standard MDS-LR care (...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-G13-MDS-LR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-LR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS G13 |
| Disease | DIS-MDS-LR |
| ESCAT tier | IIIB |
| Evidence summary | NRAS G13 in MDS-LR — progression-risk marker. No targeted therapy; standard MDS-LR care (luspatercept / HMA). |
Notes
ESCAT IIIB. Adverse for transformation risk.
Used By
No reverse references found in the YAML corpus.